Faron Pharmaceuticals Gets Green Light For New Traumakine Trial
Faron Pharmaceuticals Gets Green Light For New Traumakine Trial
Read moreWed, 11th Dec 2019 13:42
Faron Pharmaceuticals Gets Green Light For New Traumakine Trial
Read more(Sharecast News) - Faron Pharmaceuticals announced on Monday that the US Food and Drug Administration (FDA) has accepted its proposed protocol design for the next 'Traumakine' study in acute respiratory distress syndrome (ARDS) patients, following its protocol submission in February.
Read moreFaron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings
Read moreFaron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform
Read more(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has acquired rights for the potential new use of AOC3 inhibitors covered by a recently filed patent application.
Read moreFaron Pharmaceuticals Alters Traumakine Study After US FDA Feedback
Read moreFaron Pharma To Test Clevegen In Patients With Ovarian Cancer
Read moreFaron Pharma Gets Approval For Part II Trial Of Clevegen Drug
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that, further to the update on 'Traumakine' drug substance manufacturing on 2 October, it has carried out a detailed investigation into the circumstances around manufacturing arrangements.
Read moreFaron Pharma Files For Arbitration Amid Traumakine Deal Termination
Read moreFaron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance
Read moreFaron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital
Read moreFaron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status
Read moreFaron Pharmaceuticals Applies For Nasdaq First North Growth Listing
Read more